Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials. He received his MD from the University of Pennsylvania. His research is based on the underlying hypothesis that the ability to inhibit an oncogenic pathway and block cancer growth will vary based on cell lineage and the complement of mutations within the tumor. To design rational therapeutic studies, we must define not only the spectrum of genetic changes within particular tumor types but also the mechanisms by which these alterations support tumor growth, survival, metastasis, and other hallmarks of cancer.
- Member, American Society for Clinical Investigation (2011)
- Louise and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2007)
- Kimmel Scholar, Sidney Kimmel Foundation for Cancer Research (2007)
- Career Development Award, American Society of Clinical Oncology (2002)
- Young Investigator Award, American Society of Clinical (2001)